Company
Rhaeos
FlowSense assesses hydrocephalus shunt flow in minutes.
Also known as RHAEOS, INC.
- Status
- Operatingas of 2026-09-17
- Business model
- B2B
- Headquarters
- United States
- Employees
- 12Source (opens in a new tab)
- Legal name
- RHAEOS, INC.
- rhaeos.com (opens in a new tab)
- LinkedIn (opens in a new tab)
- X (opens in a new tab)
- Press page (opens in a new tab)
- Careers (opens in a new tab)
Record updated 28 September 2026
About
Rhaeos, Inc. is a VC backed, clinical stage medical device company developing FlowSense, a patent protected platform technology and a noninvasive wireless, wearable skin patch that can assess and monitor fluid flow subdermally throughout the body. The company is initially targeting hydrocephalus, a life threatening condition caused by an abnormal accumulation of cerebrospinal fluid (CSF). Implantable shunts, the gold standard treatment, often fail, leading to multiple trips to the emergency room and repeat surgeries. There is no technology available today that can easily assess CSF flow in shunts wirelessly, bedside, and without capital equipment until now.
Funding snapshot
- Total raised
- $6.2MSEC form D sum, as of 2026-09-28Source (opens in a new tab)
- Latest round
- Grant, $1.5M2023-10-09
Funding rounds
- Grant
- $1.5M2023-10-09, Company stated
- Round, 2023
- $6.2M2023-02-15, SEC form D sold, 23 investors
Products
- Hardware
- FlowSense